Health Condition 1: F20-F29- Schizophrenia, schizotypal, delusional, and other non-mood psychotic disorders
Conditions
Interventions
Intervention1: Tab. Ursodeoxycholic acid 300mg: Tab. Ursodeoxycholic acid 300mg twice daily for 6 weeks + treatment as usual.
Control Intervention1: Treatment as Usual: Treatment as Usual
Sponsors
Central Institute of Psychiatry, Ranchi
Eligibility
Inclusion criteria
Inclusion criteria: 1. Male and female inpatients satisfying ICD 11 criteria of Schizophrenia. 2. Illness duration of minimum 2 years 3. Patients who are drug free for 4 weeks of oral and 8 weeks of depot antipsychotic medications / drug naive 4. Those who give informed consent for participating in the study.
Exclusion criteria
Exclusion criteria: 1. Any other major comorbid psychiatric diagnosis and substance dependence excluding nicotine and caffeine. 2. Current or past history of severe/significant medical or neurological illness. 3. Known hypersensitivity to Tab Ursodeoxycholic acid (Urticaria, Pruritus, Erythematous rash, Angioedema, Bronchospasm, Hypotension, Anaphylaxis) 4. Contraindications to use of Ursodeoxycholic acid (Complete Billiary Obstruction, Acute Cholecystitis or Chloangitis, Calcified Gallstones, Pregnancy, Lactation, Severe Liver Disease or Decompensated Cirrhosis) 5. A patient who had received ECT in the last 6 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in Glutamate levels in DLPFC detected by MRSTimepoint: 0 and 6 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in score of PANSS, BPRS, CDSS, MOCA and CGI scalesTimepoint: 0, 4 weeks and 6 weeks. | — |
Countries
India
Contacts
Public ContactDr Santosh Kumar Sinha
Central Institute of Psychiatry, Ranchi
Outcome results
None listed